This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cross Country (CCRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cross Country Healthcare (CCRN) Lags Q2 Earnings Estimates
by Zacks Equity Research
Cross Country (CCRN) delivered earnings and revenue surprises of -28.57% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Cross Country Healthcare (CCRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cross Country Healthcare (CCRN) stock based on the movements in the options market lately.
Compared to Estimates, Cross Country (CCRN) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
New Strong Sell Stocks for February 27th
by Zacks Equity Research
CAR, CCRN and ECPG have been added to the Zacks Rank #5 (Strong Sell) List on February 27, 2023.
5 Stocks Favored by Brokers Amid the Current Uncertainty
by Maharathi Basu
We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.
Cross Country (CCRN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Cross Country (CCRN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Curious about Cross Country (CCRN) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Cross Country (CCRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
The Zacks Analyst Blog Highlights Cross Country Healthcare, HireQuest, Heidrick & Struggles, KornFerry and TrueBlue
by Zacks Equity Research
Cross Country Healthcare, HireQuest, Heidrick & Struggles, KornFerry and TrueBlue are included in this Analyst Blog.
5 Staffing Stocks to Gain as Labor Market Remains Hot
by Tirthankar Chakraborty
Keep an eye on staffing stocks like Cross Country Healthcare (CCRN), HireQuest (HQI), Heidrick & Struggles International (HSII), KornFerry International (KFY) and TrueBlue (TBI), banking on solid January jobs growth.
Compared to Estimates, Cross Country (CCRN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Cross Country (CCRN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Analysts Estimate Cross Country Healthcare (CCRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cross Country (CCRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 7th
by Zacks Equity Research
BANR, COLM and CCRN have been added to the Zacks Rank #5 (Strong Sell) List on August 7, 2023.
Cross Country (CCRN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cross Country Healthcare (CCRN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cross Country (CCRN) delivered earnings and revenue surprises of 13.11% and 2.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Kforce (KFRC) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Kforce (KFRC) delivered earnings and revenue surprises of -3.06% and 1.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cross Country Healthcare (CCRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cross Country (CCRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boise Cascade and Cross Country Healthcare have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boise Cascade and Cross Country Healthcare are part of the Zacks Bull and Bear of the Day article.
Bear Of The Day: Cross Country Healthcare (CCRN)
by Brian Bolan
I was shocked to see this stock with the lowest Zacks Rank considering it was a 221% winner for Stocks Under $10.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
ATSG, CCRN and FSFG have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.
New Strong Sell Stocks for May 11th
by Zacks Equity Research
ASLE, BSET and CCRN have been added to the Zacks Rank #5 (Strong Sell) List on May 11, 2023.
New Strong Sell Stocks for May 8th
by Zacks Equity Research
CCRN, EL and LOVE have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2023.
Cross Country Healthcare (CCRN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cross Country (CCRN) delivered earnings and revenue surprises of 10.53% and 4.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Insperity, Inc. (NSP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insperity, Inc. (NSP) delivered earnings and revenue surprises of 7.66% and 0.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Insperity, Kforce and Cross Country Healthcare
by Zacks Equity Research
Insperity, Kforce and Cross Country Healthcare have been highlighted in this Industry Outlook article.